HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ELMD

Electromed, Inc.

Healthcare — Medical Devices

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

None 3 analysts
$28.51
+$0.28 (+0.99%)
Target: $40.33 (41.5%)

Price History

52-Week Range
Sign in to add ELMD to a watchlist or set price alerts.

Fundamentals

Market Cap$364.90M
P/E Ratio (TTM)37.67
Forward P/E72.25
EPS (TTM)$1.17
Dividend Yield-
Profit Margin14.08%
Revenue Growth18.40%
ROE21.70%
Debt/Equity0.17
Recommendation None
Analyst Target$40.33
Analysts3
Next Earnings Aug 25, 2026 AMC
Indexes -

Technical Indicators

RSI (14)87.4
Beta0.52
SMA 20-
SMA 40-
52-Week High$44.59
52-Week Low$17.73
50-Day Avg$34.24
200-Day Avg$27.96
Avg Volume63.2K
Volume115.1K

Performance Analysis

NEUTRAL

ELMD presents a mixed picture with both positive and negative indicators.

~ Trading at 40% of its 52-week range.
- RSI at 87.4 indicates overbought conditions — a pullback may be due.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
~ Modest revenue growth of 18.4% year-over-year.
~ Wall Street consensus is "none" from 3 analysts.
+ Average analyst target of $40.33 implies 41.5% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:07 UTC

Back to Screener Export Report